AU2017223838B2 - Treatment of neurodegenerative eye disease using pridopidine - Google Patents

Treatment of neurodegenerative eye disease using pridopidine Download PDF

Info

Publication number
AU2017223838B2
AU2017223838B2 AU2017223838A AU2017223838A AU2017223838B2 AU 2017223838 B2 AU2017223838 B2 AU 2017223838B2 AU 2017223838 A AU2017223838 A AU 2017223838A AU 2017223838 A AU2017223838 A AU 2017223838A AU 2017223838 B2 AU2017223838 B2 AU 2017223838B2
Authority
AU
Australia
Prior art keywords
pridopidine
subject
eye
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017223838A
Other languages
English (en)
Other versions
AU2017223838A1 (en
Inventor
Michal Geva
Ralph Laufer
Aric ORBACH
Hermann Kurt Russ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of AU2017223838A1 publication Critical patent/AU2017223838A1/en
Assigned to PRILENIA THERAPEUTICS DEVELOPMENT LTD. reassignment PRILENIA THERAPEUTICS DEVELOPMENT LTD. Request for Assignment Assignors: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Assigned to PRILENIA NEUROTHERAPEUTICS LTD. reassignment PRILENIA NEUROTHERAPEUTICS LTD. Amend patent request/document other than specification (104) Assignors: PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Application granted granted Critical
Publication of AU2017223838B2 publication Critical patent/AU2017223838B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
AU2017223838A 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine Active AU2017223838B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299290P 2016-02-24 2016-02-24
US62/299,290 2016-02-24
PCT/US2017/019266 WO2017147366A1 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Publications (2)

Publication Number Publication Date
AU2017223838A1 AU2017223838A1 (en) 2018-09-06
AU2017223838B2 true AU2017223838B2 (en) 2022-09-29

Family

ID=59686581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017223838A Active AU2017223838B2 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Country Status (10)

Country Link
US (1) US11738012B2 (enExample)
EP (1) EP3419622B1 (enExample)
JP (1) JP7034488B2 (enExample)
AU (1) AU2017223838B2 (enExample)
CA (1) CA3015512C (enExample)
DK (1) DK3419622T3 (enExample)
ES (1) ES2979123T3 (enExample)
HU (1) HUE066769T2 (enExample)
PL (1) PL3419622T3 (enExample)
WO (1) WO2017147366A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US20220062255A1 (en) * 2016-02-24 2022-03-03 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) * 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
WO2023062632A1 (en) * 2021-10-11 2023-04-20 Prilenia Neurotherapeutics Ltd. Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
EP2170343A1 (en) 2007-05-31 2010-04-07 Joseph Weinstock Treatment of age-related macular degeneration
US20090062400A1 (en) 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
MX2015003812A (es) 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3854785A1 (en) * 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
KR20200031446A (ko) 2018-09-14 2020-03-24 삼성전자주식회사 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mueller, B (2014) 'Neuroprotective properties of sigma-1 receptor in glaucoma' [obtained from internet on 03 November 2021] <URL: http://digitalcommons.hsc.unt.edu/cgi/viewcontent.cgi?article=1758&context=theses> *
Sahlholm, K et al (2015) "Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses." Psychopharmacology 232(18): 3443-53. doi:10.1007/s00213-015-3997-8 *

Also Published As

Publication number Publication date
EP3419622B1 (en) 2024-03-06
ES2979123T3 (es) 2024-09-24
DK3419622T3 (da) 2024-06-03
EP3419622A4 (en) 2019-07-10
CA3015512C (en) 2024-01-16
PL3419622T3 (pl) 2024-07-08
JP7034488B2 (ja) 2022-03-14
CA3015512A1 (en) 2017-08-31
HUE066769T2 (hu) 2024-09-28
AU2017223838A1 (en) 2018-09-06
WO2017147366A1 (en) 2017-08-31
US11738012B2 (en) 2023-08-29
US20190046516A1 (en) 2019-02-14
EP3419622A1 (en) 2019-01-02
JP2019507758A (ja) 2019-03-22

Similar Documents

Publication Publication Date Title
US11738012B2 (en) Treatment of neurodegenerative eye disease using pridopidine
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2019518730A (ja) 眼の炎症性障害および疾患の組合せ処置
US11654140B2 (en) Treatment of ocular inflammatory diseases using laquinimod
US20180140593A1 (en) Treatment of Glaucoma Using Laquinimod
US20220062255A1 (en) Treatment of neurodegenerative eye disease using pridopidine
US20240261273A1 (en) Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
Mashael Systemic Medications and Their Ocular Side Effects
AU2025217391A1 (en) Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PRILENIA THERAPEUTICS DEVELOPMENT LTD.

Free format text: FORMER APPLICANT(S): TEVA PHARMACEUTICALS INTERNATIONAL GMBH

HB Alteration of name in register

Owner name: PRILENIA NEUROTHERAPEUTICS LTD.

Free format text: FORMER NAME(S): PRILENIA THERAPEUTICS DEVELOPMENT LTD.

FGA Letters patent sealed or granted (standard patent)